SILVER SPRING, MD — Unanimously disappointed with the end point used to determine clinical benefit, advisors to the US Food and Drug Administration (FDA) agreed the Sentinel Cerebral Protection System ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Regional variations in market growth reflect differences in healthcare infrastructure and adoption rates, with North America and Asia-Pacific leading the way. Companies operating in the market ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

WASHINGTON, DC—An exploratory analysis of the PROTECTED TAVR trial suggests that use of the Sentinel cerebral embolic protection system (Boston Scientific) during TAVI had a greater impact in patients ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW YORK CITY -- ...

TCT 319: Short -Term Clinical Effect of Cerebral Embolic Protection Device Following Transcatheter Aortic-Valve Replacement in Korea Population: The Sentinel Registry (Sentinel) Receive the the latest ...

An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective capture of embolic debris and does not change neurocognitive function for ...

Please provide your email address to receive an email when new articles are posted on . In patients having TAVR, cerebral embolic protection reduced risk for periprocedural stroke in patients from the ...

United States Embolic Protection Device Market is expected to reach US$ 650 million by 2033 from US$ 360 million in 2024, with a CAGR of 6.96% from 2025 to 2033. Rising cardiovascular operations, ...

CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within ...